podcasts Ratings /ratings/en/research-insights/podcasts/2019-08-01-the-sp-pharma-dose-episode-32-pfizer-finds-home-for-upjohn-though-lessened-diversity-results-in-lower-rating content esgSubNav
In This List

The S&P Pharma Dose – Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating

COMMENTS

A Sudden Correction To Fast-Rising U.S. Home Prices Isn't Likely

COMMENTS

COVID-19 Impact: Key Takeaways From Our Articles

RESUPD

Research Update: Australian Postal Corp. Outlook Revised To Stable On Strong Parcel Earnings; 'A+/A-1' Ratings Affirmed

What's It Worth? The Rise Of Electric Vehicles In European Auto ABS

Listen: The S&P Pharma Dose – Episode 32: Pfizer Finds Home For Upjohn, Though Lessened Diversity Results In Lower Rating

The S&P Pharma Guy, Arthur Wong, shares S&P Global’s thoughts on Pfizer Inc.’s announcement it was spinning off Upjohn, home to legacy products Lipitor, Viagra, and Lyrica. Pfizer remains a pharma giant and leading player in the industry. However, the lessened diversity will result in a lower rating. 

Register with S&P Global Ratings

Register now to access exclusive content, events, tools, and more.

Go Back